An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Latest Information Update: 12 Dec 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Dec 2024 Timeframe for primary endpoint has been updated from 1 year to up to 100 weeks.
- 13 Oct 2023 Status changed from active, no longer recruiting to completed.
- 01 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.